Tags Archive Navigation
icon
-
Media ReleaseNovartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
-
Media ReleaseNovartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis
-
Media ReleaseNovartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
-
Media ReleaseNovartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
-
StoryPhotographer Captures Patients Around the World Persevering With ITP
-
StoryThe future of chronic myeloid leukemia is evolving
-
StoryStriving to vanquish leukemia
-
StoryNeed for new heart disease medicines drives wave of potential therapies
-
StoryNovartis Access impact evaluation: progress update on our work with Boston University
-
StoryNovartis invites scrutiny of effort to improve access to medicine
-
StoryPositive gains are needed to accelerate change for women with lung disease
-
StoryTargeting the roots of Sjögren’s syndrome